stockrowImmunityBio, Inc.
IBRX Healthcare Biotechnology
ImmunityBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $113.3 million, up 668.3% from fiscal 2024.
- Revenue
- +93.9%
- EPS
- −120.0%
- Free cash flow
- +13.4%
- Total debt
- +57.4%
Quarter to June 2026, against a year earlier
Follow IBRX
Alert me
ImmunityBio, Inc. (IBRX) EBITDA
ImmunityBio, Inc.'s EBITDA for fiscal 2025 was −$240.5M, compared with −$304.0M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$235.2M. Over the past ten years it has ranged from −$315.6M (fiscal 2021) to −$88.4M (fiscal 2018); the current reading is higher than 45% of that period. ImmunityBio, Inc. ranks 530th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$240.5M | — |
| FY2024 | −$304.0M | — |
| FY2023 | −$300.5M | — |
| FY2022 | −$315.4M | — |
| FY2021 | −$315.6M | — |
| FY2020 | −$207.3M | — |
| FY2019 | −$142.2M | — |
| FY2018 | −$88.4M | — |
| FY2017 | −$92.0M | — |
| FY2016 | −$118.7M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | −$55.8M | — |
| Mar 2026 | −$66.9M | — |
| Dec 2025 | −$60.8M | — |
| Sep 2025 | −$51.7M | — |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| KRYS Krystal Biotech, Inc. compare | $234.3M |
| CAI Caris Life Sciences,�Inc. compare | $180.0M |
| TGTX TG Therapeutics, Inc. compare | $136.0M |
| PTGX Protagonist Therapeutics, Inc. compare | $56.4M |
| TWST Twist Bioscience Corporation compare | −$119.6M |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −$145.8M |
| IBRX ImmunityBio, Inc. | −$235.2M |
| SYRE Spyre Therapeutics, Inc. compare | −$250.2M |
| CYTK Cytokinetics, Incorporated compare | −$694.7M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on IBRX
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement